BCP
ACRS icon

Berylson Capital Partners’s Aclaris Therapeutics ACRS Stock Holding History

Berylson Capital Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-193,872
Closed -$1.16M – 21
2019
Q1 		$1.16M Buy
+193,872
New +$1.29M 1.37% 27

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Berylson Capital Partners's ACRS Position: Q2 2019 in Review

Berylson Capital Partners sold out of Aclaris Therapeutics (ACRS) in Q2 2019, closing a stake of 193,872 shares — an estimated $1.16M sold.

Berylson Capital Partners first reported a position in ACRS in Q1 2019 and held it in 1 quarter. The position peaked at $1.16M in Q1 2019. 84 funds tracked by Wall St. Rank hold ACRS as of Q2 2019.

  • Berylson Capital Partners reported no remaining Aclaris Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Berylson Capital Partners sold 193,872 Aclaris Therapeutics shares in Q2 2019, an estimated $1.16M.
  • Berylson Capital Partners first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 1 quarter.
  • Berylson Capital Partners's Aclaris Therapeutics position peaked at $1.16M in Q1 2019.
  • 84 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2019.

Based on Berylson Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.